(Q34858352)

English

The effectiveness of tofacitinib, a novel Janus kinase inhibitor, in the treatment of rheumatoid arthritis: a systematic review and meta-analysis

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

4 August 2017

7 references

13 March 2019

17 June 2019

30 June 2019

17 September 2019

28 September 2019

2 October 2019

17 December 2020

0 references

The effectiveness of tofacitinib, a novel Janus kinase inhibitor, in the treatment of rheumatoid arthritis: a systematic review and meta-analysis (English)

1 reference

Europe PubMed Central

PubMed publication ID

4 August 2017

0 references

rheumatoid arthritis

6 references

13 March 2019

17 June 2019

30 June 2019

17 September 2019

28 September 2019

2 October 2019

heterocyclic compound

1 reference

17 September 2019

1 reference

28 September 2019

mechanism of action

1 reference

2 October 2019

1 reference

17 December 2020

1 reference

17 December 2020

systematic review

1 reference

based on heuristic

inferred from title

4

object named as

Andrzej Pilc

1 reference

Europe PubMed Central

PubMed publication ID

4 August 2017

1

object named as

Paweł Kawalec

1 reference

Europe PubMed Central

PubMed publication ID

4 August 2017

author name string

Alicja Mikrut

2

1 reference

Europe PubMed Central

PubMed publication ID

4 August 2017

Natalia Wiśniewska

3

1 reference

Europe PubMed Central

PubMed publication ID

4 August 2017

language of work or name

1 reference

based on heuristic

inferred from title

publication date

23 July 2013

1 reference

Europe PubMed Central

PubMed publication ID

4 August 2017

1 October 2013

7 references

13 March 2019

17 June 2019

30 June 2019

17 September 2019

28 September 2019

2 October 2019

17 December 2020

Clinical Rheumatology

8 references

Europe PubMed Central

PubMed publication ID

4 August 2017

13 March 2019

17 June 2019

30 June 2019

17 September 2019

28 September 2019

2 October 2019

17 December 2020

32

1 reference

Europe PubMed Central

PubMed publication ID

4 August 2017

10

1 reference

Europe PubMed Central

PubMed publication ID

4 August 2017

1415-1424

1 reference

Europe PubMed Central

PubMed publication ID

4 August 2017

copyright license

Creative Commons Attribution-NonCommercial 2.0 Generic

23 July 2013

1 reference

April 2022 Public Data File from Crossref

copyright status

0 references

Safety profile of protein kinase inhibitors in rheumatoid arthritis: systematic review and meta-analysis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3778229

8 July 2018

A pharmacokinetic and clinical assessment of tofacitinib for the treatment of rheumatoid arthritis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3778229

8 July 2018

Tofacitinib (CP-690,550) in patients with rheumatoid arthritis receiving methotrexate: twelve-month data from a twenty-four-month phase III randomized radiographic study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3778229

8 July 2018

Systematic review and network meta-analysis of combination and monotherapy treatments in disease-modifying antirheumatic drug-experienced patients with rheumatoid arthritis: analysis of American College of Rheumatology criteria scores 20, 50, and 70

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3778229

8 July 2018

JAK inhibitor tofacitinib for treating rheumatoid arthritis: from basic to clinical

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3778229

8 July 2018

Tofacitinib for the treatment of rheumatoid arthritis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3778229

8 July 2018

2012 update of the 2008 American College of Rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3778229

8 July 2018

Systematic review and meta-analysis of the efficacy and safety of existing TNF blocking agents in treatment of rheumatoid arthritis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3778229

8 July 2018

Inhibition of JAK kinases in patients with rheumatoid arthritis: scientific rationale and clinical outcomes

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3778229

8 July 2018

Co-administration of the JAK inhibitor CP-690,550 and methotrexate is well tolerated in patients with rheumatoid arthritis without need for dose adjustment

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3778229

8 July 2018

A meta-analysis of the efficacy and safety of using infliximab for the treatment of rheumatoid arthritis.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3778229

8 July 2018

Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3778229

8 July 2018

The safety and efficacy of a JAK inhibitor in patients with active rheumatoid arthritis: Results of a double-blind, placebo-controlled phase IIa trial of three dosage levels of CP-690,550 versus placebo

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3778229

8 July 2018

Assessing the quality of reports of randomized clinical trials: is blinding necessary?

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3778229

8 July 2018

The american rheumatism association 1987 revised criteria for the classification of rheumatoid arthritis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3778229

8 July 2018

American College of Rheumatology. Preliminary definition of improvement in rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1007%2FS10067-013-2329-9

21 January 2018

Tofacitinib (CP-690,550) in combination with methotrexate in patients with active rheumatoid arthritis with an inadequate response to tumour necrosis factor inhibitors: a randomised phase 3 trial

1 reference

https://api.crossref.org/works/10.1007%2FS10067-013-2329-9

21 January 2018

Improved pain, physical functioning and health status in patients with rheumatoid arthritis treated with CP-690,550, an orally active Janus kinase (JAK) inhibitor: results from a randomised, double-blind, placebo-controlled trial.

1 reference

https://api.crossref.org/works/10.1007%2FS10067-013-2329-9

21 January 2018

A proposed revision to the ACR20: The hybrid measure of American College of Rheumatology response

1 reference

https://api.crossref.org/works/10.1007%2FS10067-013-2329-9

21 January 2018

Tofacitinib or Adalimumab versus Placebo in Rheumatoid Arthritis

1 reference

https://api.crossref.org/works/10.1007%2FS10067-013-2329-9

21 January 2018

Discontinuation of anti-TNF-α therapy in a Chinese cohort of patients with rheumatoid arthritis

1 reference

https://pubmed.ncbi.nlm.nih.gov/23877486

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Phase II study of tofacitinib (CP-690,550) combined with methotrexate in patients with rheumatoid arthritis and an inadequate response to methotrexate

1 reference

https://pubmed.ncbi.nlm.nih.gov/23877486

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A phase IIb dose-ranging study of the oral JAK inhibitor tofacitinib (CP-690,550) versus placebo in combination with background methotrexate in patients with active rheumatoid arthritis and an inadequate response to methotrexate alone

1 reference

https://pubmed.ncbi.nlm.nih.gov/23877486

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Phase IIb dose-ranging study of the oral JAK inhibitor tofacitinib (CP-690,550) or adalimumab monotherapy versus placebo in patients with active rheumatoid arthritis with an inadequate response to disease-modifying antirheumatic drugs

1 reference

https://pubmed.ncbi.nlm.nih.gov/23877486

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Placebo-controlled trial of tofacitinib monotherapy in rheumatoid arthritis

1 reference

https://pubmed.ncbi.nlm.nih.gov/23877486

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1007/S10067-013-2329-9

1 reference

Europe PubMed Central

PubMed publication ID

4 August 2017

PMC publication ID

1 reference

Europe PubMed Central

PubMed publication ID

4 August 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

4 August 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q34858352&oldid=1960765996"